Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease...

|By:, SA News Editor

Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease drug Esbriet gained approval with a Germany review committee. The action clears a path for the treatment to be approved by the nation's health insurers and helps increase confidence that France will also allow the therapy.